Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trialMichel Bazinet, Andrew Vaillant, Pavlina Jimbei et al.|The Lancet. Gastroenterology & hepatology|2017Cited by 249
Prevention of Herpes Simplex Virus Induced Stromal Keratitis by a Glycoprotein B-Specific Monoclonal AntibodyAdalbert Krawczyk, Dirk Bauer|PLoS ONE|2015Cited by 29
Superior antiviral activity of IFNβ in genital HSV-1 infectionYasmin Schmitz, Kathrin Sutter, Mara Schwerdtfeger et al.|Frontiers in Cellular and Infection Microbiology|2022Cited by 7